World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024

Table of Contents

1 Executive Summary

2 AMD and Diabetic Retinopathy

• 2.1 The Eye
  • 2.1.1 The Human Eye
  • 2.1.2 The Retina and Vision
• 2.2 Age-Related Macular Degeneration (AMD)
  • 2.2.1 Early Stages of AMD
  • 2.2.2 Advanced Dry AMD (Geographic Atrophy)
  • 2.2.3 Wet AMD
  • 2.2.4 AMD Causes and Risk Factors
• 2.3 Diabetic Retinopathy (DR)
  • 2.3.1 Causes and Types of Diabetic Retinopathy
  • 2.3.2 Non-Proliferative Diabetic Retinopathy
  • 2.3.3 Diabetic Macular Edema
  • 2.3.4 Proliferative Diabetic Retinopathy (PDR)
  • 2.3.5 Risk Factors and Prevalence of Diabetic Retinopathy
• 2.4 Diagnosis and Prevalence of AMD and DR
  • 2.4.1 Diagnosis
  • 2.4.2 Prevalence
• 2.5 Other Retinal Disorders

3 Treatments for AMD and Diabetic Retinopathy

• 3.1 Treatment of Wet AMD
  • 3.1.1 Visudyne
  • 3.1.2 Macugen
  • 3.1.3 Retaane
  • 3.1.4 Lucentis
  • 3.1.5 Avastin
• 3.2 Treatment of Dry AMD
• 3.3 Treatments for Diabetic Retinopathy
  • 3.3.1 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy
  • 3.3.2 Triamcinolone Acetonide
  • 3.3.3 Lisinopril
  • 3.3.4 VEGF Inhibitors
• 3.3.5 Dobesilate

4 The World AMD and Diabetic Retinopathy Market, 2009-2024

• 4.1 The Retinal Disorder Market
  • 4.1.1 The Retinal Disorder Market in 2008
  • 4.1.2 Retinal Disorders Market Forecast, 2009-2014
  • 4.1.3 Retinal Disorders Market Forecast, 2014-2024
• 4.2 The World AMD Market, 2008
  • 4.2.1 Leading AMD Drugs in 2008
  • 4.2.2 Leading AMD Drug Manufacturers
• 4.3 AMD Market Forecast
  • 4.3.1 New Treatments for Geographic Atrophy: AMD Market Forecast, 2009-2014
  • 4.3.2 AMD Market Forecast, 2014-2024
• 4.4 Diabetic Retinopathy Market
  • 4.4.1 The Diabetic Retinopathy Market in 2008
  • 4.4.2 An Alternative to Surgery: Diabetic Retinopathy Market Forecast, 2009-2014
  • 4.4.3 Diabetic Retinopathy Market Forecast, 2014-2024
• 4.5 Lucentis Sales Forecasts
  • 4.5.1 The Future of Lucentis Hinges on Off-Label Avastin Use
  • 4.5.2 Lucentis Sales Forecast, 2009-2014
  • 4.5.3 Lucentis Sales Forecast, 2014-2024
  • 4.5.4 Alternative Lucentis Sales Forecast, 2009-2024
• 4.6 Visudyne Sales Forecast, 2009-2014

5 The AMD and Diabetic Retinopathy Pipelines

• 5.1 The Wet AMD Pipeline
  • 5.1.1 Monoclonal Antibodies and Corticosteroid Implants
  • 5.1.2 siRNA Molecules
  • 5.1.3 Stem Cells and Other Therapies
• 5.2 The Dry AMD Pipeline
• 5.3 The Diabetic Retinopathy Pipeline
  • 5.3.1 Corticosteroid Implants
  • 5.3.2 Anti-VEGF Treatments
  • 5.3.3 Early-Stage Diabetic Retinopathy Pipeline
• 5.4 The Pipeline for Other Retinal Disorders
• 5.5 AMD and DR Pipeline Drugs in Detail
  • 5.5.1 VEGF Trap-Eye/Aflibercept (Regeneron/Bayer)
  • 5.5.2 Posurdex/SK-0503 (Allergan/Sanwa Kagaku Kenkyusho)
  • 5.5.3 Bevasiranib (Opko)
  • 5.5.4 Avastin and Lucentis Comparison Trials (CATT)
  • 5.5.5 PF-4523655 (Quark/Pfizer)
  • 5.5.6 Visudyne and Lucentis (QLT/Novartis)
  • 5.5.7 Pazopanib (GSK)
  • 5.5.8 TG100801 (TargeGen)
  • 5.5.9 Zybrestat (Oxigene/Symphony ViDA)
  • 5.5.10 ATG-3 (CoMentis)
  • 5.5.11 Sirolimus (MacuSight/Santen)
  • 5.5.12 Iluvien (Alimera/pSivida)
  • 5.5.13 NT-501 (Neurotech)
  • 5.5.14 OT-551 (Othera)
  • 5.5.15 Sustained-Release Brimonidine (Allergan)
  • 5.5.16 Fenretinide (Sirion Therapeutics)
  • 5.5.17 NT-503 (Neurotech)
  • 5.5.18 Stem Cells (University College of London/Pfizer)
  • 5.5.19 Opko' s siRNA Drug Candidates
  • 5.5.20 Arxxant (Eli Lilly/Alcon/Takeda)
  • 5.5.21 Lucentis (Roche/Novartis)
  • 5.5.22 Macugen (Pfizer)
  • 5.5.23 Vitreosolve (Vitreoretinal Technologies)
  • 5.5.24 Atacand/TCV-116 (AstraZeneca)
  • 5.5.25 Microplasmin (ThromboGenics)
  • 5.5.26 RPE65 Gene Therapy (Targeted Genetics)
  • 5.5.27 QLT091001 (QLT/Retinagenix)

6 Issues Affecting the AMD and Diabetic Retinopathy Pharmaceutical Markets

• 6.1 SWOT Analysis of the AMD and Diabetic Retinopathy Pharmaceutical Markets
• 6.2 Intense Research and Development Activity
  • 6.2.1 New Drug Formulations
  • 6.2.2 Sustained-Release Ocular Implants
  • 6.2.3 Novel Biologic Drugs
  • 6.2.4 New Ophthalmic Therapeutic Applications for Drugs
• 6.3 Off-Label Avastin Use for Retinal Disorders
  • 6.3.1 Avastin and Lucentis
  • 6.3.2 Off-Label Retinal Applications of Avastin
  • 6.3.3 History of Avastin Use for Wet AMD
  • 6.3.4 The CATT Study
  • 6.3.5 The Future for Off-Label Avastin
• 6.4 ' Greying' of the World Population
• 6.5 Prevalence of Retinal Diseases
  • 6.5.1 Prevalence of AMD, 2008
  • 6.5.2 Forecast AMD Prevalence, 2024
  • 6.5.3 Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Edema, 2008
  • 6.5.4 Forecast Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Edema, 2024
• 6.6 Reimbursement for AMD and Diabetic Retinopathy Pharmaceuticals
  • 6.6.1 Pressure on Healthcare in Current Difficult Economic Environment
  • 6.6.2 Prospects for Reimbursement for AMD and DR Drugs
• 6.7 Diagnosis and Screening for Retinal Disorders
• 6.8 Laser and Surgical Treatments for Diabetic Retinopathy Will Compete with New Drugs
  • 6.8.1 Current Laser Treatments
  • 6.8.2 Will Drugs Replace Laser Therapy?

7 AMD and Diabetic Retinopathy Regional Markets

• 7.1 Retinal Disorder Country Markets, 2008
• 7.2 Retinal Disorder Regional Forecast, 2009-2024
  • 7.2.1 The US Retinal Disorder Market, 2009-2024
  • 7.2.2 The European Retinal Disorder Market, 2009-2024
  • 7.2.3 The Retinal Disorder Market in the Rest of the World, 2009-2024

8 Opinion from Industry Experts

• 8.1 Edward Danse, President and CEO of Neurotech
  • 8.1.1 Retinal Disorders with Greatest Unmet Patient Need
  • 8.1.2 Neurotech' s AMD Pipeline
  • 8.1.3 Progress of NT-501 Clinical Trials in Geographic Atrophy Patients
  • 8.1.4 Screening Programmes for AMD
  • 8.1.5 Potential Lifetime of NT-501 in the Eye
  • 8.1.6 Other Potential Treatments for Geographic Atrophy
  • 8.1.7 Potential Use of NT-501 in Diabetic Retinopathy
• 8.2 Ken Green, Ph.D., Chief Scientific Officer and Dave Holland, Founder/VP Marketing, Alimera Sciences
  • 8.2.1 Main Unmet Clinical Needs Among Diabetic Retinopathy Patients
  • 8.2.2 Development of Iluvien for Diabetic Macular Edema
  • 8.2.3 Update on Progress of Iluvien' s Phase III Trials
  • 8.2.4 Reimbursement Prospects for Corticosteroid Inserts
  • 8.2.5 Future for Laser Therapy in Diabetic Retinopathy
  • 8.2.6 Possible Future Treatment for Dry AMD and Geographic Atrophy
  • 8.2.7 Clinical Trials for Iluvien for Wet AMD and RVO
• 8.3 Al Reaves, Ph.D., Senior Vice President of Clinical Development, Othera Pharmaceuticals
  • 8.3.1 Othera' s Geographic Atrophy Drug: OT-551
  • 8.3.2 New Drugs for Retinal Disorders Currently with No Treatments

9 Conclusions

• 9.1 AMD and Diabetic Retinopathy
• 9.2 Increasing Prevalence of AMD and Diabetic Retinopathy
• 9.3 Current Treatments for AMD and Diabetic Retinopathy
• 9.4 The Retinal Disorder Market in 2008
• 9.5 Retinal Disorders Market Forecast, 2009-2024
• 9.6 Lucentis Market Forecast, 2009-2024
• 9.7 The AMD and Diabetic Retinopathy Pipelines
• 9.8 The AMD Pipeline
• 9.9 The Diabetic Retinopathy Pipeline

List of Tables

• Table 2.1 Wet AMD Types
• Table 2.2 AMD and DR Diagnosis Methods
• Table 2.3 Prevalence of AMD and DR, 2008
• Table 2.4 Other Retinal Disorders
• Table 3.1 Currently-Marketed AMD Treatments
• Table 3.2 Lucentis Regulatory Approval and Launch Dates
• Table 4.1 Retinal Disorder Market in 2008
• Table 4.2 World Retinal Disorders Market Forecast, 2009-2014
• Table 4.3 World Retinal Disorders Market Forecast, 2015-2024
• Table 4.4 AMD Market, 2008: Leading Drugs
• Table 4.5 AMD Market, 2008: Leading Manufacturers
• Table 4.6 Drivers and Restraints for the AMD Market, 2009-2014
• Table 4.7 Drivers and Restraints for the DR Market, 2009-2014
• Table 4.8 Drivers and Restraints for Lucentis Revenues, 2009-2014
• Table 4.9 Lucentis Market Forecast (Main Forecast), 2009-2014
• Table 4.10 Lucentis Market Forecast (Main Forecast), 2015-2024
• Table 4.11 Lucentis Market Forecast (Alternative Forecast), 2009-2014
• Table 4.12 Lucentis Market Forecast (Alternative Forecast), 2015-2024
• Table 4.13 Visudyne Market Forecast, 2009-2014
• Table 5.1 Key Late-Stage AMD Pipeline Drugs
• Table 5.2 Selected Early-Stage AMD Pipeline Drugs
• Table 5.3 Key Late-Stage Diabetic Retinopathy Pipeline Drugs
• Table 5.4 Selected Early-Stage DR Pipeline Drugs
• Table 5.5 Other Retinal Disorder Pipeline Drugs
• Table 5.6 Lucentis Clinical Trials in Progress
• Table 6.1 SWOT Chart for the AMD and DR Pharmaceutical Markets, 2009
• Table 6.2 World Population Forecast, 2008-2024
• Table 6.3 Population Forecasts in AMD and DR Markets, 2008 & 2024
• Table 6.4 Global, US and European AMD Prevalence, 2008
• Table 6.5 Forecast Global, US and European AMD Prevalence, 2024
• Table 6.6 Global, US and European DME, PDR and Diabetes Prevalence, 2008
• Table 6.7 Forecasted Global, US and European DME, PDR and Diabetes Prevalence, 2024
• Table 7.1 Leading Retinal Disorder Pharmaceutical Markets, 2008
• Table 7.2 Regional Retinal Disorders Market Forecast, 2009-2014
• Table 7.3 Regional Retinal Disorders Market Forecast, 2015-2024
• Table 9.1 Global Prevalence of AMD and DR Complications, 2008 and 2024

List of Figures

• Figure 4.1 Retinal Disorder Market in 2008
• Figure 4.2 World Retinal Disorder Market Forecast, 2009-2024
• Figure 4.3 Revenue Forecast by Retinal Disorder Type, 2009-2024
• Figure 4.4 Market Share Forecast by Retinal Disorder Type, 2009-2024
• Figure 4.5 AMD Market, 2008: Leading Drugs
• Figure 4.6 AMD Market, 2008: Leading Manufacturers
• Figure 4.7 Global AMD Market Forecast, 2009-2024
• Figure 4.8 Global DR Market Forecast, 2009-2024
• Figure 4.9 Lucentis Market Forecast (Main Forecast), 2009-2024
• Figure 4.10 Lucentis Market Forecast (Alternative Forecast), 2009-2024
• Figure 4.11 Visudyne Market Forecast, 2009-2014
• Figure 6.1 Forecasted World Population Aged 65 or Over, 2008-2024
• Figure 6.2 Population Forecasts in Leading AMD and DR Markets, 2008 & 2024
• Figure 6.3 Global, US and European AMD Prevalence, 2008
• Figure 6.4 Global, US and European AMD Prevalence, 2008 and 2024
• Figure 6.5 Global, US and European DME and PDR Prevalence, 2008
• Figure 6.6 Global, US and European Diabetes Prevalence, 2008 and 2024
• Figure 6.7 Global, US and European New Cases of DME, 2008 and 2024
• Figure 6.8 Global, US and European New Cases of PDR, 2008 and 2024
• Figure 7.1 Leading Retinal Disorder Pharmaceutical Markets, 2008
• Figure 7.2 Regional Retinal Disorders Market Forecast, 2009-2014
• Figure 7.3 Market Share Forecast by Regional Retinal Disorder Market, 2009-2024
• Figure 9.1 World Retinal Disorder Market Forecast, 2009-2024
• Figure 9.2 Lucentis Market Forecast, 2009-2024

Companies Listed

• Alcon (Nestle)
• Alimera Sciences
• Allergan
• American Academy of Ophthalmology (AAO)
• American Society of Retinal Specialists (ASRS)
• AstraZeneca
• Bausch & Lomb
• Bayer
• BioDiem
• Bristol-Myers Squibb
• Centre for Molecular and Vascular Biology, KU Leuven
• Chugai
• CoMentis
• Diabetic Retinopathy Clinical Research Network (DRCR)
• Eli Lilly
• Emory University
• ESBATech
• Esteve
• European Medicines Agency (EMEA)
• Eyetech
• Food and Drug Administration (FDA)
• Fovea
• Gene Signal
• Genentech
• GenVec
• Gilead
• GlaxoSmithKline (GSK)
• iCo
• Isis
• Jerini Ophthalmic
• KAI Pharmaceuticals
• Lpath
• Ludwig-Maximilians-Universitat
• MacuSight
• Merck & Co.
• Moorfields Eye Hospital
• National Eye Institute (NEI)
• National Health Service (NHS)
• National Institute for Health and Clinical Excellence (NICE)
• National Institute for Health Research (NIHR)
• National Institutes of Health (NIH)
• Neurotech
• NeXstar
• Novartis
• OM Pharmaceuticals
• Ophthotech
• Opko
• OSI Pharmaceuticals
• Othera
• Oxford BioMedica
• Oxigene
• Pfizer
• Potentia
• pSivida
• QLT
• Quark
• Regeneron
• Retinagenix
• Roche
• Santen
• Sanwa Kagaku Kenkyusho
• Shire
• Sirion Therapeutics
• Sirna Therapeutics
• Sirnaomics
• Suzuken
• Symphony ViDA
• Takeda
• TargeGen
• Targeted Genetics
• ThromboGenics
• University College London
• University of Florida
• University of Kentucky College of Medicine
• Vitreoretinal Technologies
• Wyeth